Search Results

Filter
  • 1-10 of  160 results for ""Antigens, CD19""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Evaluation of Nonviral piggyBac and lentiviral Vector in Functions of CD19chimeric Antigen Receptor T Cells and Their Antitumor Activity for CD19 + Tumor Cells.

  • Authors : Lin Z; Medical, Cell Product and R&D Department, Center for Cell Pharmaceuticals, Shanghai Cell Therapy Group, Shanghai, China.; Liu X

Subjects: Antigens, CD19/Antigens, CD19/Antigens, CD19/*immunology ; Immunotherapy, Adoptive/Immunotherapy, Adoptive/Immunotherapy, Adoptive/*methods ; Neoplasms/Neoplasms/Neoplasms/*therapy

  • Source: Frontiers in immunology [Front Immunol] 2022 Jan 10; Vol. 12, pp. 802705. Date of Electronic Publication: 2022 Jan 10 (Print Publication: 2021).Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet

Record details

×
Academic Journal

A second CD19 CAR T-cell infusion: yes or no?

Subjects: Antigens, CD19* ; Neoplasms*; B-Lymphocytes

  • Source: Blood [Blood] 2021 Jan 21; Vol. 137 (3), pp. 284-286.Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020

Record details

×
Academic Journal

Discovery and characteristics of B cell-like T cells: A potential novel tumor immune marker?

  • Authors : Liu Y; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Oncology Department, Tianjin, China.; Ye S

Subjects: Antigens, CD19/Antigens, CD19/Antigens, CD19/*immunology ; Antigens, CD19/Antigens, CD19/Antigens, CD19/*metabolism ; B-Lymphocyte Subsets/B-Lymphocyte Subsets/B-Lymphocyte Subsets/*immunology

  • Source: Immunology letters [Immunol Lett] 2020 Apr; Vol. 220, pp. 44-50. Date of Electronic Publication: 2020 Jan 31.Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 7910006 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins.

  • Authors : Klesmith JR; Department of Chemical Engineering and Materials Science , University of Minnesota Twin Cities , 421 Washington Avenue SE , Minneapolis , Minnesota 55455 , United States.; Su L

Subjects: Antigens, CD19/Antigens, CD19/Antigens, CD19/*metabolism ; Immunotherapy, Adoptive/Immunotherapy, Adoptive/Immunotherapy, Adoptive/*methods ; Neoplasms/Neoplasms/Neoplasms/*therapy

  • Source: Molecular pharmaceutics [Mol Pharm] 2019 Aug 05; Vol. 16 (8), pp. 3544-3558. Date of Electronic Publication: 2019 Jul 15.Publisher: American Chemical Society Country of Publication: United States NLM ID: 101197791 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization.

  • Authors : Leung WH; bluebird bio, inc., Cambridge, Massachusetts, USA.; Gay J

Subjects: Antigens, CD19/Antigens, CD19/Antigens, CD19/*immunology ; Immunotherapy, Adoptive/Immunotherapy, Adoptive/Immunotherapy, Adoptive/*methods ; Neoplasms/Neoplasms/Neoplasms/*therapy

  • Source: JCI insight [JCI Insight] 2019 Apr 30; Vol. 5. Date of Electronic Publication: 2019 Apr 30.Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium:

Record details

×
Academic Journal

What CAR Will Win the CD19 Race?

Subjects: Antigens, CD19/Antigens, CD19/Antigens, CD19/*immunology ; Neoplasms/Neoplasms/Neoplasms/*therapy ; Receptors, Antigen, T-Cell/Receptors, Antigen, T-Cell/Receptors, Antigen, T-Cell/*therapeutic use

  • Source: Molecular cancer therapeutics [Mol Cancer Ther] 2019 Mar; Vol. 18 (3), pp. 498-506.Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19‑positive malignancies.

  • Authors : Wang S; Department of Internal Medicine V, Heidelberg University Hospital, D-69120 Heidelberg, Germany.; Sellner L

Subjects: Antigens, CD19/Antigens, CD19/Antigens, CD19/*metabolism ; Hydrazines/Hydrazines/Hydrazines/*pharmacology ; Immunotherapy, Adoptive/Immunotherapy, Adoptive/Immunotherapy, Adoptive/*methods

  • Source: Oncology reports [Oncol Rep] 2021 Aug; Vol. 46 (2). Date of Electronic Publication: 2021 Jun 24.Publisher: D.A. Spandidos Country of Publication: Greece NLM ID: 9422756 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials.

Subjects: Clinical Trials as Topic*/Clinical Trials as Topic*/Clinical Trials as Topic*/statistics & numerical data; Antigens, CD19/Antigens, CD19/Antigens, CD19/*immunology ; Immunotherapy, Adoptive/Immunotherapy, Adoptive/Immunotherapy, Adoptive/*methods

  • Source: Experimental cell research [Exp Cell Res] 2018 Aug 01; Vol. 369 (1), pp. 1-10. Date of Electronic Publication: 2018 May 31.Publisher: Academic Press Country of Publication: United States NLM ID: 0373226 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.

  • Authors : Kagoya Y; Tumor Immunotherapy Program, Campbell Family Institute for Breast Cancer Research, Campbell Family Cancer Research Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.; Tanaka S

Subjects: Antigens, CD19/Antigens, CD19/Antigens, CD19/*genetics ; Interleukin-2 Receptor beta Subunit/Interleukin-2 Receptor beta Subunit/Interleukin-2 Receptor beta Subunit/*genetics ; Neoplasms/Neoplasms/Neoplasms/*therapy

  • Source: Nature medicine [Nat Med] 2018 Mar; Vol. 24 (3), pp. 352-359. Date of Electronic Publication: 2018 Feb 05.Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

Overcoming the challenges associated with CD3+ T-cell redirection in cancer.

  • Authors : Singh A; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Dees S

Subjects: Antibodies, Bispecific/Antibodies, Bispecific/Antibodies, Bispecific/*therapeutic use ; Antigens, CD19/Antigens, CD19/Antigens, CD19/*immunology ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*therapeutic use

  • Source: British journal of cancer [Br J Cancer] 2021 Mar; Vol. 124 (6), pp. 1037-1048. Date of Electronic Publication: 2021 Jan 19.Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited

Record details

×
  • 1-10 of  160 results for ""Antigens, CD19""